According to incomplete statistics from Innovation Radar, last week (May 26 to June 1) in the global pharmaceuticals and healthcare sectorA total of 31 financing events were disclosed, with a total amount exceeding 8.4 billion US dollars.Of which 65% of the funds flow into innovative drug research and development.

Continuous Breakthroughs in Gene Therapy and Oligonucleotide Technology。AusperBio(AusperBio) Secures $50 Million in Series B+ Financing to Advance the Continuous Clinical Development of Non-Conjugated Antisense Oligonucleotide (ASO) Drug AHB-137 for the Treatment of Chronic Hepatitis B;Boin BioCompleted tens of millions of yuan in angel+ round financing, developing non-viral vector gene therapies, focusing on addressing the three major pain points in the field: vector capacity limitations, inability to re-administer, and high production costs.RNativesSecures €1.4 Million in Seed Funding for RNA Gene Regulation Therapy.

Active Financing in the Central Nervous System Field: A Total of 8 Companies Involved with Relatively Concentrated BusinessesThree of the companies are focused on the research and development of small molecule targeted drugs for neurological diseases, with amounts all exceeding 50 million U.S. dollars. GRIN Therapeutics completed a 140-million-U.S.-dollar D-round financing to develop allosteric modulators that improve neuronal signal transmission by regulating NMDA receptor function for the treatment ofGRINSevere Neurodevelopmental Disorders Caused by Gene Mutations. Syndeio Biosciences Completes Over $90 Million Financing to Develop Synapse-Targeting Small Molecule Drugs for Intervening in Abnormal Neuronal Synaptic Connections, Treating Schizophrenia and Depression. Vima Therapeutics Raises $60 Million in Series A Funding to Develop Oral Dystonia Treatment Drug VIM0423, Targeting Muscarinic Cholinergic Receptors in the Brain. Xijia Medical and Salvia BioElectronics Enter from Digital Therapeutics and Device Ends, Focusing on Unmet Clinical Needs.

Large Financing Round Successfully Raised in the Protein Degradation FieldGlycoEra Leads Europe with $130 Million Series B Financing, Backed by Roche, Bristol-Myers Squibb, and Other Institutions, Expanding Indications to Autoimmune Disease Field. Its Bifunctional Degrader Can Capture Pathogenic Protein Targets on the Extracellular and Cell Membrane, Precisely and Continuously Removing Pathogenic Proteins While Avoiding Off-Target Effects.

Milestone of PegBio Co., Ltd.'s Hong Kong Stock Listing in Metabolic Chronic Disease Drug DevelopmentPegBio Co., Ltd. listed on the Hong Kong Stock Exchange, raising a net amount of approximately HKD 2.32 billion, focusing on endocrine and metabolic diseases. The company develops long-acting therapies through peptide and small molecule drugs. Its core pipeline product, PB-119 Injection (Vipenatide), is a once-weekly long-acting GLP-1 receptor agonist, mainly used for first-line treatment of type 2 diabetes and obesity.

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share this to their WeChat Moments. Unauthorized media or organizations are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact:"InnoVantage"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommendations

Click "InSee", Share the latest health trends from Biotech Innovation Hub